Брахитерапия рака прямой кишки: сравнительная характеристика методик (обзор литературы)
https://doi.org/10.33878/2073-7556-2023-22-3-158-175
Аннотация
Анализ литературы свидетельствует об отсутствии отечественных публикаций, освещающих роль брахитерапии в лечении больных раком прямой кишки (РПК). Целью представленной работы явилась необходимость восполнить этот пробел и систематизировать имеющуюся информацию относительно различных аспектов клинического применения двух основных вариантов брахитерапии РПК.
Об авторах
Р. В. Новиков
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России; ФГБОУ ВПО «Военно-медицинская академии имени С. М. Кирова» МО РФ
Россия
Россия
Ленинградская ул., д. 68, Песочный пос., г. Санкт-Петербург, 197758
ул. Академика Лебедева, д. 6, г. Санкт-Петербург, 194175
С. Н. Новиков
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России
Россия
Россия
Ленинградская ул., д. 68, Песочный пос., г. Санкт-Петербург, 197758
Список литературы
1. Каприн А.Д. Состояние онкологической помощи населению России в 2020 году / А.Д. Каприн, В.В. Старинский, А.О. Шахзадова. − М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. – 239 с.
2. Клинические рекомендации. Рак прямой кишки 2022. https://cr.minzdrav.gov.ru.
3. Berger N.F., Sylla P. The role of transanal endoscopic surgery for early rectal cancer. Clin Colon Rectal Surg 2022; 35(2): 113-121. doi: 10.1055/s-0041-1742111.
4. Самсонов Д.В., Моисеенко А.Б., Карачун А.М. Стратегия «Watch & Wait» в радикальном лечении рака прямой кишки: добиваемся полного ответа всеми способами? Вопросы онкологии, 2022. Том 68, № 5 с. 548-554. doi.org/10.37469/0507-3758-2022-68-5-548-554.
5. Stewart A.J., Van Limbergen E.J., Gerard J.P. et al. GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. Clin Transl Radiat Oncol 2021; 33: 15-22. DOI: 10.1016/j.ctro.2021.12.004.
6. Vuong T., Garant A., Vendrely V. et al. Clinical applications of high dose rate endorectal brachytherapy for patients with rectal cancer. Cancer Radiother. 2022: S1278-3218 (22) 00153-6. DOI: 10.1016/j.canrad.2022.07.001.
7. Morimoto M., Isohashi F., Yoshioka Y. et al. Salvage high-dose-rate interstitial brachytherapy for locally recurrent rectal cancer: long-term follow-up results. Int J Clin Oncol 2014; 19 (2): 312-8. DOI: 10.1007/s10147-013-0567-0.
8. Petric P., Al-Hammadi N., Spindler K.G., Lindegaard J.C. Anal cancer brachytherapy: From radon seeds to interstitial Papillon technique in a century. What does the future hold? Radiother Oncol. 2022; 169: 25-34. DOI: 10.1016/j.radonc.2022.02.006.
9. Gérard J.P., Barbet N., Dejean C. et al. Contact X-ray brachytherapy for rectal cancer: Past, present, and future. Cancer Radiother 2021; 25 (8): 795-800. DOI: 10.1016/j.canrad.2021.04.006.
10. Vuong T., Garant A., Vendrely V. et al. Image-Guided Brachytherapy for Rectal Cancer: Reviewing the Past Two Decades of Clinical Investigation. Cancers (Basel) 2022; 14 (19): 4846. DOI: 10.3390/cancers14194846.
11. Garant A., Vasilevsky C.A., Boutros M. et al. MORPHEUS phase II-III study: a pre-planned interim safety analysis and preliminary results. Cancers (Basel) 2022; 14 (15): 3665. DOI: 10.3390/cancers14153665.
12. Gerard J.P., Barbet N.N., Pacé-Loscos T. et al. Contact x-ray brachytherapy (Papillon) in addition to chemoradiotherapy to improve organ preservation in early cT2-T3 rectal adenocarcinoma: The 3-year results of OPERA randomized trial (NCT02505750). J Clin Oncol 2022; 40 (16): 3512. DOI: 10.1200/JCO.2022.40.16.
13. Forsstell G. La lutte social contre le cancer. J de Radiologie 1931;15.
14. Chaoul H., Adam H. Die Roentgen-Nahbestrahlung maligner tumoren. Strahlenth 1933; 48: 31-50.
15. Gérard J.P., Myint A.S., Croce O. et al. Renaissance of contact x-ray therapy for treating rectal cancer. Expert Rev Med Devices 2011; 8 (4): 483-92. DOI: 10.1586/erd.11.28.
16. Gérard J.P., Dejean C., Montagne L. et al. A brief history of contact X-ray brachytherapy 50 kVp. Cancer Radiother 2020; 24 (3): 222-225. DOI: 10.1016/j.canrad.2020.01.002.
17. Lamarque P.L., Gros C.G. La radiothérapie de contact des cancers du rectum. J Elect Radiol 1946; 27: 333-48.
18. Papillon J. Intracavitary irradiation of early rectal cancer for cure. A series of 186 cases. Cancer 1975; 36: 696-701.
19. Gerard J.P., Chapet O., Nemoz C. et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 2004; 22 (12): 2404-9. DOI: 10.1200/JCO.2004.08.170.
20. Eaton D.J. Electronic brachytherapy-current status and future directions. Br J Radiol 2015; 88 (1049): 20150002. DOI: 10.1259/bjr.20150002.
21. Walstam R. Remotely-controlled afterloading radiotherapy apparatus. (A preliminary report). Phys Med Biol 1962; 7: 225-8. DOI: 10.1088/0031-9155/7/2/308.
22. Kaufman N., Nori D., Shank B. et al. Remote afterloading intraluminal brachytherapy in the treatment of rectal, rectosigmoid, and anal cancer: a feasibility study. Int J Radiat Oncol Biol Phys 1989; 17 (3): 663-8. DOI: 10.1016/0360-3016(89)90121-1.
23. Yanagi H., Kusunoki M., Kamikonya N. et al. Results of preoperative intraluminal brachytherapy combined with radical surgery for middle and lower rectal carcinomas. J Surg Oncol 1997; 65 (2): 76-81. DOI: 10.1002/(sici)1096-9098(199706)65:2<76::aid-jso2>3.0.co;2-k.
24. Vuong T., Belliveau P.J., Michel R.P. et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum 2002; 45 (11): 1486-93. DOI: 10.1007/s10350-004-6455-y.
25. Poon E., Reniers B., Devic S. et al. Dosimetric characterization of a novel intracavitary mold applicator for 192Ir high dose rate endorectal brachytherapy treatment. Med Phys 2006; 33 (12): 4515-26. DOI: 10.1118/1.2364054.
26. Bellezzo M., Fonseca G.P., Verrijssen A.S. et al. A novel rectal applicator for contact radiotherapy with HDR 192Ir sources. Brachytherapy 2018; 17(6): 1037-1044. DOI: 10.1016/j.brachy.2018.07.012.
27. Bellezzo M., Fonseca G.P., Voncken R. et al. Advanced design, simulation, and dosimetry of a novel rectal applicator for contact brachytherapy with a conventional HDR 192Ir source. Brachytherapy 2020; 19(4): 544-553. DOI: 10.1016/j.brachy.2020.03.009.
28. Webster M.J., Devic S., Vuong T. et al. HDR brachytherapy of rectal cancer using a novel grooved-shielding applicator design. Med Phys 2013; 40 (9): 091704. DOI: 10.1118/1.4816677.
29. Webster M.J., Devic S., Vuong T. et al. Dynamic modulated brachytherapy (DMBT) for rectal cancer. Med Phys 2013; 40 (1): 011718. DOI: 10.1118/1.4769416.
30. Jakobsen A., Mortensen J.P., Bisgaard C. et al. Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. Int J Radiat Oncol Biol Phys 2006; 64 (2): 461-5. DOI: 10.1016/j.ijrobp.2005.07.969.
31. Hoskin P.J., de Canha S.M., Bownes P. et al. High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Radiother Oncol 2004; 73 (2): 195-8. DOI: 10.1016/j.radonc.2004.06.004.
32. Sun Myint A., Lee C.D., Snee A.J. et al. High dose rate brachytherapy as a boost after preoperative chemoradiotherapy for more advanced rectal tumours: the Clatterbridge experience. Clin Oncol (R Coll Radiol) 2007; 19 (9): 711-9. DOI: 10.1016/j.clon.2007.07.018.
33. Omidvari S., Zohourinia S., Ansari M. et al. Efficacy and safety of low-dose-rate endorectal brachytherapy as a boost to neoadjuvant chemoradiation in the treatment of locally advanced distal rectal cancer: a phase-ii clinical trial. Ann Coloproctol 2015; 31 (4): 123-30. DOI: 10.3393/ac.2015.31.4.123.
34. Dossa F., Chesney T.R., Acuna S.A., Baxter N.N. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017; 2 (7): 501-513. DOI: 10.1016/S2468-1253(17)30074-2.
35. van der Valk M., Hilling D.E., Bastiaannet E. et al. IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545. DOI: 10.1016/S0140-6736(18)31078-X.
36. Chadi S.A., Malcomson L., Ensor J. et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2018; 3 (12): 825-836. DOI: 10.1016/S2468-1253(18)30301-7.
37. Appelt A., Pløen J., Vogelius I.R. et al. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):74-80. doi: 10.1016/j.ijrobp.2012.05.017.
38. Mandard A.M., Dalibard F., Mandard J.C. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73 (11): 2680-6. DOI: 10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820 731105>3.0.co;2-c.
39. Appelt A., Jakobsen A., Gerard J.P., Sebag-Montefiore D. Is there a radiation dose-response relationship for non-operative management of rectal cancer? Radiotherapy and Oncology 152:S76-S77. DOI:10.1016/S0167-8140(21)00186-9.
40. Michalski J.M., Gay H., Jackson A. et al. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010; 76 (3 Suppl): S123-9. DOI: 10.1016/j.ijrobp.2009.03.078.
41. Withers H.R., Taylor J.M., Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 1988; 14 (4): 751-9. DOI: 10.1016/0360-3016(88)90098-3.
42. Джойнер М.С., ван дер Когель О. Дж. Основы клинической радиобиологии. Глава 14. Влияние объема облучаемой ткани в лучевой терапии. – М.: БИНОМ. Лаборатория знаний, 2013. – 600 с.
43. Dale R.G. The radiobiology of Papillon-type treatments. Clin Oncol (R Coll Radiol) 2007; 19 (9): 649-54. DOI: 10.1016/j.clon.2007.07.010.
44. Van Limbergen E.J., Hazelaar C., Vaassen F. et al. Endorectal contact radiation boosting: Making the case for dose AND volume reporting. Brachytherapy 2022: S1538-4721 (22)00147-7. doi: 10.1016/j.brachy.2022.08.004.
45. Benson A.B., Venook A.P., Al-Hawary M.M. et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw 2020; 18(7): 806-815. DOI: 10.6004/jnccn.2020.0032.
46. Wo J.Y., Anker C.J., Ashman J.B. et al. Radiation Therapy for rectal cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol 2021; 11(1): 13-25. DOI: 10.1016/j.prro.2020.08.004.
47. Glynne-Jones R., Wyrwicz L., Tiret E. et al. ESMO guidelines committee. rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl 4): iv263. DOI: 10.1093/annonc/mdy161.
48. Chinese Watch & Wait Database Research Cooperation Group(CWWD); Chinese Association , of Surgeons, Chinese Society of Coloproctology, Chinese Medical Doctor Association; Chinese Society of Colorectal Surgery, Chinese Medical Association; Colorectal Cancer Physician Specialty Committee, Chinese Medical Doctor Association; Radiation Therapy Specialty Committee, Chinese Anticancer Association. [Consensus on the Watch and Wait policy in rectal cancer patients after neoadjuvant treatment (2020 version)]. 2020; 23(1): 1-9. DOI: 10.3760/cma.j.issn.1671-0274.2020.01.001.
49. Podda M., Sylla P., Baiocchi G. et al. Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of Emergency Surgery) International Consensus Project. World J Emerg Surg 2021; 16(1): 35. DOI: 10.1186/s13017-021-00378-9.
50. Zhang S.C., Atkins K.M., Chung, E.M. et al. Emerging role of brachytherapy in the nonoperative management of rectal cancer. Curr Colorectal Cancer Rep 2022. DOI.org/ 10.1007/ s11888-022-00479-w.
51. Fokas E., Glynne-Jones R., Fleischmann M. et al. Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives. Cancer Treat Rev 2023; 112: 102490. doi: 10.1016/j.ctrv.2022.102490.
52. Jankowski M., Pietrzak L., Rupiński M. et al. Watch-and-wait strategy in rectal cancer: Is there a tumour size limit? Results from two pooled prospective studies. Radiother Oncol 2021; 160: 229-235. DOI: 10.1016/j.radonc.2021.05.014.
53. Habr-Gama A., São Julião G.P., Vailati B.B. et al. Organ preservation among patients with clinically node-positive rectal cancer: is it really more dangerous? // Dis Colon Rectum. 2019. Vol. 62, No. 6, pp. 675-683. doi: 10.1097/DCR.0000000000001337.
54. McCawley N., Clancy C., O'Neill B.D. et al. mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis // Dis Colon Rectum 2016; 59 (12): 1200-1208. DOI: 10.1097/DCR. 0000000000000635.
55. Самсонов Д.В., Карачун А.М., Правосудов И.В. и соавт. Прогностическое значение постлучевого регресса местнораспространенного рака прямой кишки. Вопросы онкологии, 2019. том 65, № 1 с. 135-141. doi.org/10.37469/0507-3758-2019-65-1-135-141.
56. Papillon J. Present status of radiation therapy in the conservative management of rectal cancer. Radiother Oncol 1990; 17 (4): 275-83. DOI: 10.1016/0167-8140(90)90001-d.
57. Sun Myint A., Smith F.M., Gollins S.W. et al. Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation? Br J Radiol 2017; 90 (1080): 20170175. DOI: 10.1259/bjr.20170175.
58. Gérard J.P., Barbet N., Gal J. et al. Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study. Eur J Cancer 2019; 108: 1-16. DOI: 10.1016/j.ejca. 2018.11.022.
59. Myint A.S., Dhadda A.S., Stewart A. et al. New hope from OPERA trial for surgically fit rectal cancer patients who wish to have organ preservation. Colorectal Dis 2022. DOI: 10.1111/codi.16286.
60. Buckley H., Wilson C., Ajithkumar T. High-dose-rate brachytherapy in the management of operable rectal cancer: a systematic review. Int J Radiat Oncol Biol Phys 2017; 99 (1): 111-127. DOI: 10.1016/j.ijrobp.2017.05.023.
61. Appelt A.L., Pløen J., Harling H. et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol 2015; 16 (8): 919-27. DOI: 10.1016/S1470-2045(15)00120-5.
62. Dizdarevic E., Frøstrup Hansen T., Pløen J. et al. Long-term patient-reported outcomes after high-dose chemoradiation therapy for nonsurgical management of distal rectal cancer. Int J Radiat Oncol Biol Phys 2020; 106 (3): 556-563. DOI: 10.1016/j.ijrobp.2019.10.046.
63. Vuong T., Devic S., Moftah B. et al. High-dose-rate endorectal brachytherapy in the treatment of locally advanced rectal carcinoma: technical aspects. Brachytherapy 2005; 4 (3): 230-5. DOI: 10.1016/j.brachy.2005.03.006.
64. Garant A., Magnan S., Devic S. et al. Image guided adaptive endorectal brachytherapy in the nonoperative management of patients with rectal cancer. Int J Radiat Oncol Biol Phys 2019; 105 (5): 1005-1011. DOI: 10.1016/j.ijrobp.2019.08.042.
65. Rijkmans E.C., Cats A., Nout R.A. et al. Endorectal brachytherapy boost after external beam radiation therapy in elderly or medically inoperable patients with rectal cancer: primary outcomes of the phase 1 HERBERT study. Int J Radiat Oncol Biol Phys 2017; 98 (4): 908-917. DOI: 10.1016/j.ijrobp.2017.01.033.
66. Rijkmans E.C., Marijnen C.A.M., van Triest B. et al. Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study. Radiother Oncol 2019; 133: 176-182. DOI: 10.1016/j.radonc.2019.01.034.
67. Garcia-Aguilar J., Patil S., Gollub M.J. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23): 2546-2556. DOI: 10.1200/JCO.22.00032.
68. Verrijssen A.S., Opbroek T., Bellezzo M. et al. A systematic review comparing radiation toxicity after various endorectal techniques. Brachytherapy 2019; 18 (1): 71-86.e5. DOI: 10.1016/j.brachy.2018.10.001.
69. Corner C., Bryant L., Chapman C. et al. High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy 2010; 9 (1): 66–70. DOI:10.1016/j.brachy.2009.07.004.
70. Fleischmann M., Diefenhardt M., Trommel M. et al. Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach. Strahlenther Onkol 2022; 198 (7): 654-662. DOI: 10.1007/s00066-022-01931-4.
71. Новиков Р.В., Тюряева Е.И., Арсеньев А.И. и соавт. Методологические аспекты лучевого лечения рака прямой кишки с использованием эндолюминальной высокомощностной адаптивной брахитерапии (опыт НМИЦ онкологии им. Н.Н. Петрова). Лучевая диагностика и терапия 2023. (принята в печать).
Дополнительные файлы
Рецензия
При поддержке: нет
Для цитирования:
Новиков Р.В., Новиков С.Н. Брахитерапия рака прямой кишки: сравнительная характеристика методик (обзор литературы). Колопроктология. 2023;22(3):158-175. https://doi.org/10.33878/2073-7556-2023-22-3-158-175
For citation:
Novikov R.V., Novikov S.N. Brachytherapy of rectal cancer: comparative characteristics of techniques (review). Koloproktologia. 2023;22(3):158-175. https://doi.org/10.33878/2073-7556-2023-22-3-158-175
Просмотров: 28
Послать статью по эл. почте 
